⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27396526 | 0.98 | CYP3A4 (0.38) | — | |
| SCHEMBL19969031 | 0.98 | CYP3A4 (0.38) | — | |
| SCHEMBL20980413 | 0.98 | CYP3A4 (0.38) | — | |
| SCHEMBL15783570 | 0.98 | CYP3A4 (0.38) | — | |
| SCHEMBL26025176 | 0.98 | CYP3A4 (0.38) | — | |
| SCHEMBL21342076 | 0.93 | CYP3A4 (0.39) | — | |
| SCHEMBL20234586 | 0.91 | SOAT1 (0.34) | — | |
| SCHEMBL1826675 | 0.88 | CYP3A4 (0.42) | — | |
| SCHEMBL2449256 | 0.87 | ALDH1A1 (0.37) | — | |
| SCHEMBL2990809 | 0.86 | TSHR (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022235699-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022056273-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021000067-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | 杭州多禧生物科技有限公司 | 2021-01-07 | — | — | WO | disclosed |
| US-9782493-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-24 | — | — | US | disclosed |
| US-8193214-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-05 | — | — | US | disclosed |
| US-20100029637-A1 | Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20090192202-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-30 | — | — | US | disclosed |
| US-7507860-B2 | Androgen modulators | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2008098112-A2 | POSITRON EMISSION TOMOGRAPHY IMAGING METHOD | PURDUE RESEARCH FOUNDATION (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070197641-A1 | Androgen modulators | HU LAIN-YEN | 2007-08-23 | — | — | US | disclosed |
| EP-1737813-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100305-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6852726-B2 | Substituted indoles as alpha-1 agonists | SYNTEX LLC (US) | 2005-02-08 | — | — | US | disclosed |
| CN-1143861-C | Silanyl-triazines as light screening compositions | - | 2004-03-31 | — | — | CN | disclosed |
| US-20030220319-A1 | Substituted indoles as alpha-1 agonists | SYNTEX (U.S.A.) LLC | 2003-11-27 | — | — | US | disclosed |
| CN-1227843-A | Silanyl-triazines as light screening compositions | HOFFMANN LA ROCHE (CH) | 1999-09-08 | — | — | CN | disclosed |